Stolle Research & Development Corporation

Dcv, Inc.

Stolle Milk Biologics, Inc.

Other

Southern Research Institute

Dcv Biologics, L.p.

Lee R Beck

Ralph J Stolle

Donald R Cowsar

Charles F Flowers, Jr

Albert C Tanquary

Thomas R Tice

Danny H Lewis

J Peter Fuhrer

William E Meyers

Shinji Murosaki

Thomas A Davis

Donald P Kotler

Yoshio Hidaka

Kikuo Nomoto

Yasunobu Yoshikai

Atsunori Ishida

Chiharu Kubo

The invention relates to the use of hyperimmune milk derived from milk producing animals hyperimmunized with bacterial antigens including intestinal bacteria. The present hyperimmune milk effectively prevents the decline of immunological functions observed in aging or immunocompromised animals and prevents the translocation of indigenous enteric bacteria from the GI tract of immunocompromised or aged animals, thereby preventing indigenous infection. More specifically, the present hyperimmune milk is administered to an animal in an amount sufficient to effectively prevent translocation of indigenous enteric bacteria in, delay the onset of, lower the rate of, or restore the declining immune functions of, aging or otherwise immunocompromised animals.

Use of hyperimmune milk to prevent suppression of T-lymphocyte production

An immune suppressive product prepared by injecting an allergen or a mixture of allergens into the body of milk-producing species. Said product being the milk or a polypeptide subfraction of milk obtained from the allergen treated host. The immune suppressive product(s) is milk and or the polypeptide fractions contained therein, which is ostensively free of the intact allergen or allergens used for the treatment of the host. The immune suppressive factor(s) being a subfraction of the allergen used for the treatment. A method of preparing immune suppressive polypeptides from intact allergens, which involves injection of the specific intact allergens into a milk-producing species, collecting the immune suppressive polypeptide fractions of the intact allergens from the milk of the treated host. The immune suppressive milk containing said polypeptide fractions, and/or the polypeptide fractions obtained from said milk, are nonreactive in animals and humans as allergens. Said factor(s), however, are highly effective in preventing or alleviating allergic reactions.

Immune suppressive product

The invention relates to an anti-inflammatory factor isolated from milk, methods of purifying the anti-inflammatory factor resulting in substantially or highly purified preparations and to methods for using this factor to remove adhered neutrophils from endothelial cells, to prevent the emigration of cells from the vasculature and to suppress the response of lymphocytes to foreign antigens.

Anti-inflammatory factor, method of isolation, and use

The present invention is directed to the treatment of vascular disorders particularly arteriosclerosis and atherosclerosis in warm-blooded animals. The invention encompasses the ingestion, by warm-blooded animals, of eggs or egg fractions derived from female avians that have been hyperimmunized with specific bacterial antigens or groups of bacterial antigens. The invention is directed to methods of controlling cholesterol levels, lipid deposits, and the development of atheromatous lesions in warm-blooded animals by the ingestion of eggs or fractions thereof produced in female avians hyperimmunized with specific bacterial antigens. The invention is also directed to methods of producing the eggs and to vaccines for hyperimmunization of the female avians.

Anti-cholesterolemic egg, vaccine and method for production, and use

Eggs that affect lipid and cholesterol levels obtained from avian species that are hyperimmunized against a variety of bacterial antigens are disclosed. These eggs are useful as a dietary supplement for humans and other animals.

Anti-cholesterolemic eggs are disclosed, said eggs being obtained from animals hyperimmunized against at least one anti-cholesterolemic antigen. A vaccine producing said anti-cholesterblemic egg is disclosed, said vaccine comprising at least one anti-cholesterolemic antigen. Further, a dietary supplement for humans and other animals which does not elevate serum lipid, concentrations is disclosed, said supplement comprising the anti-cholesterolemic eggs or fractions thereof. A method for treating vascular disorders in humans and other animals is also disclosed which comprises administering to said subjects said anti-cholesterolemic eggs for a time and in amounts sufficient to produce anti-arteriosclerotic effects, anti-aging vascular effects, and/or serum lipid-lowering effects.

Anti-cholesterolemic eggs are disclosed, said eggs being obtained from animals hyperimmunized against at least one anti-cholesterolemic antigen. A vaccine producing said anti-cholesterolemic egg is disclosed, said vaccine comprising at least one anti-cholesterolemic antigen. Further, a dietary supplement for humans and other animals which does not elevate serum lipid concentrations is disclosed, said supplement comprising the anti-cholesterolemic eggs or fractions thereof. A method for treating vascular disorders in humans and other animals is also disclosed which comprises administering to said subjects said anti-cholesterolemic eggs for a time and in amounts sufficient to produce anti-arteriosclerotic effects, anti-aging vascular effects, and/or serum lipid-lowering effects.

Anti-cholesterolemic vaccine

The invention relates to an anti-inflammatory factor isolated from milk and to methods for using this factor to remove adhered neutrophils from endothelial cells, to prevent the emigration of cells from the vasculature and to suppress the response of lymphocytes to foreign antigens.

The invention relates to a substantially pure anti-inflammatory factor isolated from milk collected from a milk producing animal, to the purification, identification, and characterization of said factor, and to a method for treating inflammation in an animal which comprises administering to the animal an anti-inflammatorally effective amount of the anti-inflammatory factor. In a preferred embodiment, the factor is isolated from milk is produced by a milk producing animal maintained in a hyperimmunized state.

A process for the production of a polyvalent vaccine effective in the prevention and treatment of mastitis in bovine animals is disclosed, which comprises periodically culturing the milk of animals exhibiting preclinical mastitis to cultivate any pathogens present therein, killing those pathogens and incorporating each strain of cultivated, killed pathogen in a pharmacological carrier together with all other strains previously identified. The process is repeated to ensure all newly appearing pathogenic strains are vaccinated against. The vaccine so produced has been demonstrated to be effective in reversal of hard udder syndrome.

Growing community of inventors

Lebanon, OH, United States of America

Lee R Beck